Combined treatment with lenalidomide (LEN) and epoetin alfa (EA) is superior to lenalidomide alone in patients with erythropoietin (Epo)-refractory, lower risk (LR) non-deletion 5q [Del(5q)] myelodysplastic syndrome (MDS): Results of the E2905 Intergroup Study - an ECOG-ACRIN Cancer Research Group study, grant CA180820, and the National Cancer Institute of the National Institutes of Health Meeting Abstract
| Authors: | List, A. F.; Sun, Z.; Verma, A.; Bennett, J. M.; McGraw, K. L.; Nardelli, L. A.; Maciejewski, J. P.; Altman, J. K.; Cheema, P.; Claxton, D. F.; Komrokji, R. S.; Luger, S.; Mattison, R.; Wassenaar, T.; Artz, A.; Schiffer, C. A.; Tallman, M. S. |
| Abstract Title: | Combined treatment with lenalidomide (LEN) and epoetin alfa (EA) is superior to lenalidomide alone in patients with erythropoietin (Epo)-refractory, lower risk (LR) non-deletion 5q [Del(5q)] myelodysplastic syndrome (MDS): Results of the E2905 Intergroup Study - an ECOG-ACRIN Cancer Research Group study, grant CA180820, and the National Cancer Institute of the National Institutes of Health |
| Meeting Title: | 58th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 128 |
| Issue: | 22 |
| Meeting Dates: | 2016 Dec 3-6 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2016-12-02 |
| Language: | English |
| ACCESSION: | WOS:000394446805021 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V128.22.223.223 |
| Notes: | Meeting Abstract: 223 -- Source: Wos |
